BLAINJECTIONINJECTABLE
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
AMJEVITA (adalimumab-atto) by Amgen is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2016.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMJEVITA is a TNF-receptor blocking monoclonal antibody (adalimumab-atto biosimilar) approved in 2016 for autoimmune and inflammatory indications. It functions by inhibiting tumor necrosis factor signaling to reduce inflammation. The product is a biosimilar referencing Humira, designed to provide equivalent efficacy at competitive pricing.
Peak
AMJEVITA remains in peak commercial phase with moderate competitive pressure (30/100), indicating stable market presence but ongoing pressure from competitor biosimilars requiring continued field and medical support.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AMJEVITA positions professionals in mature biosimilar market dynamics, emphasizing payer negotiation, formulary placement, and real-world evidence over early-stage innovation. Careers on this product build expertise in TNF-blocker therapeutics, biologics commercialization, and biosimilar-specific reimbursement strategies.
Brand Manager
Worked on AMJEVITA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.